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Abstract Fluoropyrimidines, including 5-fluorouracil (5-
FU), are widely used in the treatment of solid tumors
and remain the backbone of many combination regi-
mens. Despite their clinical benefit, fluoropyrimidines
are associated with gastrointestinal and hematologic
toxicities, which often lead to treatment discontinuation.
5-FU undergoes complex metabolism, dihydropyrimidine
dehydrogenase (DPD) being the rate-limiting enzyme of
inactivation of 5-FU and its prodrugs. Several studies
have demonstrated significant associations between
severe toxicities by fluoropyrimidines and germline
polymorphisms of DPD gene. To date, more than 30
SNPs and deletions have been identified within DPD,
the majority of these variants having no functional
consequences on enzymatic activity. However, the
identification of deficient DPD genotypes may help
identify poor-metabolizer patients at risk of developing
potentially life-threatening toxicities after standard doses
of fluoropyrimidines.
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Introduction
The use of fluoropyrimidines in the clinical setting
Fluoropyrimidines, including 5-fluorouracil (5-FU) and
its prodrug capecitabine, are widely used drugs to treat
cancer of the head and neck, cervix, breast and
gastrointestinal tract, alone or in combination with other
pharmacological agents, including irinotecan, oxaliplatin,
cyclophosphamide, epirubicin and the monoclonal anti-
bodies cetuximab and bevacizumab. Owing to the
widespread use of these drugs, severe toxicities are
induced by fluoropyrimidines, including nausea/vomit-
ing, diarrhea, mucositis, alopecia, myelosuppression,
cardiac toxicity and hand–foot syndrome (HFS) [1, 2].
These toxicities may limit treatment effectiveness due to
delay in drug administration and/or treatment discontinu-
ation; therefore the therapeutic benefit of fluoropyrimi-
dines is compromised. Capecitabine seems to display a
different profile of toxicity compared to 5-FU, being
characterized by a better tolerability, but higher incidence
of HFS [3]. Finally, the oral administration has some
advantage, particularly in the quality of life of patients,
and for this reason its use is becoming more diffuse in
USA and Europe.
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Mechanism of action and metabolism of fluoropyrimidines
The pharmacological activity of fluoropyrimidines (Fig. 1)
depends on the transformation of 5–FU into his active
metabolite 5–fluoro–deoxyuridine monophosphate (5–
FdUMP), which forms a stable complex with reduced
folates and thymidylate synthase (TS), the key enzyme for
de novo synthesis of thymidine. The inhibition of TS leads
to the arrest of DNA synthesis, an effect further enhanced
by the intracellular generation of fluoropyrimidine deoxy-
nucleotide analogues which are incorporated into DNA and
RNA leading to their disruption [4, 5]. It is worth noting
that the activity of fluoropyrimidines depends on the
equilibrium between anabolic and catabolic pathways. In
particular, more than 80% of an administered dose of 5–FU
is transformed to inactive metabolites, being the remaining
20% or less responsible for the therapeutic effect (Fig. 1).
The first step of 5-FU biotransformation is catalyzed by the
enzyme dihydropyrimidine dehydrogenase (DPD, Fig. 2),
which is also involved in the catabolism of thymine and
uracil. The degradation of uracil is responsible for the
endogenous biosynthesis of β-alanine, a structural analogue
of two inhibitory neurotransmitters, glycine and γ-
aminobutyric acid (GABA). 5–FU is transformed by DPD
into 5–fluoro–5,6–dihydrouracil (5–FDHU), which is fur-
ther metabolized to α-fluoro–β–alanine (FBAL) by two
additional enzymes and finally excreted by the kidneys.
The profound deficit in DPD activity is a well known
metabolic syndrome of children characterized by thymine–
uraciluria, mental retardation and high levels of thymine
and uracil in blood, urines and cerebrospinal fluid.
Therefore, the administration of fluoropyrimidines to
patients with a deficient DPD activity potentially results
in life–threatening toxicities, because a larger amount of 5–
FU is activated to cytotoxic metabolites (Fig. 2). Capeci-
tabine is an orally administered inactive prodrug that is
enzymatically converted into 5-FU [6]. Thymidine phos-
phorylase (TP) is expressed at high levels in the liver and
many tumors and catalyzes the bioactivation of capecita-
bine preferentially in cancer tissue, leading to high
concentrations of 5-FU in tumor cells [3, 5].
The clinical relevance of fluoropyrimidine toxicity
Several case reports described severe toxicities in patients
after the administration of standard doses 5–FU [7–9]. It is
likely that a significant proportion of these adverse drug
reactions are due to genetically–based differences between
individuals in the response to 5–FU. Therefore, the
prevention of life–threatening 5–FU toxicities, particularly
in the adjuvant setting, is of fundamental clinical value. For
the past 20 years, the association between DPD deficiency
and severe toxicity after 5-FU treatment, including grade
4 toxicity and death, has been extensively studied. The
frequency of low DPD enzymatic activity in the general
population was initially estimated between 3% and 5%
[10, 11], although a significant ethnic variability was
observed. Indeed, phenotypic and genotypic analyses of
Asian [12–15], African [16], European Caucasian [17] and
American [18] populations found varying frequencies of
DPD deficiency. In particular, African–Americans display
significantly lower DPD activity and higher prevalence of
DPD deficiency than Caucasians [19], whereas higher
value for DPD activity was found in a cohort of Korean
subjects. A critical issue is represented by the lack of a
current consensus definition of deficiency; some have
proposed the use of the lower 95th percentile as threshold,
while others suggested the lower 70th percentile of DPD
activity from a normal population [20]. Whatever the
value used to identify a DPD deficient patient could be, it
is worth noting that most patients have no symptoms of
partial DPD deficiency until they are challenged with a
fluoropyrimidine.
Fig. 1 Metabolic pathway of of 5-FU. 5-FdUMP/UDP/UTP: 5-
fluorodeoxyuridine-mono/di/triphosphate; 5-FUMP/UDP/UTP: 5-
fluorouridine-mono/di/triphosphate; 5-FUH2: 5,6-dihydro-5-fluorouracil
FUPA: α-fluoro-β-ureidopropionic acid; FBAL: α-fluoro-β-alanine;
DPD: dihydropyrimidine dehydrogenase; TP: thymidine phosphorylase;
TS: thymidylate synthase
Fig. 2 DPD-dependent inactivation of 5-FU and effects of DPD
deficiency. For abbreviations, see Fig. 1
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Clinical features of DPD-dependent fluoropyrimidine
toxicity
The typical toxicity in a poor or null DPD metabolizer
occurs at the first cycle of chemotherapy and it is
characterized by grade 4 (WHO) symptoms and potentially
death. Most frequent reported side effects are diarrhea grade
3 or 4, complete alopecia, mucositis grade 3 or 4, hand-foot
syndrome (Fig. 3) and neutropenia grade 3–4 [21].
Shahrokni et al. reported a case of a patient who developed
recurrent chest pain and ischemic electrocardiogram
changes after treatment with 5-FU and capecitabine.
Cardiotoxicity associated with 5-FU and capecitabine
administration is infrequently reported in the literature and
appears to be dose and schedule-dependent [22]. Öfverholm
et al. described a patient given adjuvant chemotherapy of
weekly bolus injections of 500 mg/m2 5-FU and 20 mg/m2
folinic acid; after being asymptomatic throughout the first 2
cycles, on days 3–5 after the third cycle he experienced
mild stomatitis and watering eyes. The symptoms rapidly
worsened and he was admitted to hospital care for 3 weeks
with grade 3–4 oral mucositis and grade 3–4 diarrhea. After
1 month of recovery, the treatment was reintroduced with a
50% dose reduction, a dose he could tolerate with only
minor degree of toxicity until the end of the treatment
period [23]. Another patient treated with adjuvant 5-FU
500 mg/m2 i.v. and folinic acid 60 mg/m2 i.v. on days 1 and
2, every 2 weeks, experienced grade 3 severe fatigue and
grade 2 watering eyes after two thirds of treatment [23].
Morel et al. described a patient who died from severe,
polyvisceral failure following the first administration of 5-
FU 400 mg/m2 i.v. bolus, and 22 h-infusion of 5-FU
600 mg/m2, plus 400 mg/m2 leucovorin. Seven days after
the first cycle, he was hospitalized because of grade 4
diarrhea, mucositis, grade 4 leuko/thrombocytopenia, and
dehydration. He then developed renal insufficiency and
died 7 days later, 19 days after 5-FU administration, despite
intensive supportive treatment [24].
Methods for the assessment of DPD deficiency
In vitro enzymatic activity of DPD
The first attempt to investigate DPD deficiency consisted of
the assay of DPD activity in tissues and cells or by
measuring levels of by–products of the enzymatic reaction.
It has been demonstrated that liver DPD activity is
associated with 5–FU tolerability and it is related with
enzyme activity measured in mononuclear cells of periph-
eral blood (PBMC) [25, 26], which have been used since
then as a surrogate for total body DPD. However, the
application of this method into clinical practice is labor
intensive since PBMCs are incubated ex vivo with radio-
labelled 5-FU and the resulting rate of catabolite formation
is measured by high–performance liquid chromatography
(HPLC) [27, 28]. It is likely that the need for specialized
technical skills and appropriate equipment have limited the
clinical availability of the phenotypic assay. In addition to
this, sample handling and processing are critical issues and
DPD levels in PBMCs may be even influenced by the
cellular heterogeneity of the sample since enzyme content
may vary among monocytes, lymphocytes, and neutrophils
[29]. Since the amount of DPD in tissues is dependent on
the transcriptional activity of the gene, real–time quantita-
tive PCR analysis of DPD mRNA has been proposed as a
surrogate marker of DPD activity. However, the correlation
between cellular DPD mRNA expression and DPD enzyme
activity was disappointing since conflicting data were
published in the literature [30–33]. Indeed, DPD deficiency
in patients could be caused by factors that do not change
gene expression levels, including non–synonymous variants
or drug inhibition of the enzyme (i.e., sorivudine and
brivudin). Therefore, other strategies have to be considered
to detect reduced DPD activity among patients. For this
reason, the measurement of endogenous uracil/5,6-dihy-
drouracil ratio (U/UH2) prior to the administration of 5–FU
or capecitabine has been widely investigated as a surrogate
marker of DPD activity. Indeed, enzyme deficiency impairs
the metabolic breakdown of pyrimidines, thus causing an
accumulation of uracil that can be detected in biological
matrices (plasma or urine) by HPLC. Recent studies found
that elevated levels of uracil in plasma were significantly
associated with impaired clearance of 5–FU and develop-
ment of 5–FU–related toxicity [34, 35]. Hence, the
determination of the U/UH2 ratio, measured before 5–FU
administration, may be clinically useful to prevent the
occurrence of adverse reactions.
Fig. 3 Macroscopic appearance of a palmar region of a patient with
severe hand foot syndrome
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2–13C–uracil metabolism and breath test
Another strategy is based on the evaluation of 2–13C–uracil
metabolism by measuring the exhaled levels of 13CO2 and
12CO2 using infrared spectrophotometry. Several studies
demonstrated that reduced levels of exhaled 13CO2 were
strongly correlated to partial or complete DPD deficiency,
as measured by the radiochemical enzyme assay [36]. The
breath test is non–invasive and rapid, and gives accurate results
of DPD activity within an hour after the intake of 2–13C-uracil.
Other advantages are represented by the stability of exhaled
isotopes and the easy of access of the analysis method used to
measure 2–13C–uracil, as it is the same used for the H. pylori
breath test.
However, an important disadvantage of this method is
the limited availability of the test substrate, and the inter–
assay variability among different laboratories. The latter
issue may be critical if this and other tests gain widespread
use in the clinical practice. Finally, standardized threshold
values to separate normal patients from those with DPD
deficiency are still lacking.
5-FU and 5–FDHU pharmacokinetics after 5-FU standard
or reduced test dose
Other groups of researchers attempted to investigate DPD
deficiency trough the measurement of plasma levels of 5–
FU and/or its catabolites. Several studies have demonstrat-
ed that alterations in 5–FU and 5–FDHU pharmacokinetics
were significantly associated with treatment tolerability. In
colorectal cancer patients receiving 5–FU–based adjuvant
chemotherapy, clearance (CL) and area under the time/
concentration curve (AUC) of the drug were significantly
different between patients who reported moderate–to–
severe toxicities and those who tolerated well the treatment
with fluoropyrimidines [28, 36]. These differences sug-
gested that severe adverse events were related to changes in
drug systemic exposure and elimination. As a matter of
fact, the ratio between the AUC values of the substrate 5–
FU and the metabolic product 5–FDHU was related to the
severity of toxicity better than any other pharmacokinetic
parameter, and the AUC ratio was predictive for the risk of
gastrointestinal toxicity. Furthermore, results suggested that
the pharmacokinetic analysis was more reliable and less
prone to variability than the enzyme activity assay. The
major drawback of pharmacokinetic–based strategies
depends on the evaluation of patient metabolic status upon
the first administration of therapeutic doses of 5–FU, hence
exposing subjects to possible severe toxicities. In order to
improve the safety of pharmacokinetic–based identification
of patients at risk for severe or life–threatening toxicities, a
reduced dose test was elaborated and subsequently validat-
ed in colorectal cancer patients [37–39]. This approach
helps identify patients at major risk of 5–FU–associated
toxicities on the basis of systemic pharmacokinetic markers
(i.e., AUC, CL, elimination half–life) of both 5–FU and its
inactive metabolite 5–FDHU by using a reduced drug dose
that has been demonstrated to be safe for the patient.
Finally, a recent report, using a small number of patients,
suggested the measurement of plasma levels of FBAL, the
end product of 5–FU in the catabolic pathway, by HPLC to
assess DPD enzyme activity [40]. Decreased levels of
FBAL were significantly correlated with reduced DPD
activity, as measured by radio–assay. However, this assay
requires the administration of at least a test dose of a
fluoropyrimidine.
DPD genotyping
The search for genetic variants of DPD and their associa-
tion with enzyme activity represents a clinically useful
approach to investigate DPD deficiency. The advantage
over other methods consists in the requirement of a small
blood sample for DNA extraction that can be stored at room
temperature and it does not require the precautions
necessary for an enzymatic test. The detection of DPD
sequence variants is mainly carried out by denaturing
HPLC analysis and then by automatic sequencing [41].
The gene encoding DPD is located in human chromosomal
region 1p22 and is formed by 23 exons of approximately
950 kb [42, 43]. Over 30 single nucleotide polymorphisms
(SNPs) and deletion/insertion mutations have been identi-
fied within DPD (Fig. 4, Tables 1 and 2), although most of
these variants have no functional consequences on enzy-
matic activity. The most important variant associated with
substantially reduced enzyme activity in heterozygous
patients and lack of detectable activity in homozygous
subjects is the IVS14+1G>A (DPYD*2A), which has been
found in up to 40–50% of subjects with partial or complete
DPD deficiency [20, 44, 45] (Table 2). This mutation
changes the invariant splice donor site from GT to AT,
leading to the skipping of exon 14 immediately upstream of
the mutated splice donor site in the process of DPD pre-
mRNA splicing. As a result, the mature DPD mRNA lacks
a 165-bp segment encoding the amino acids 581–635 and
the mutant DPD protein has no residual enzymatic activity,
as no significant DPD-dependent metabolism is measured
in patients with this polymorphism. A toxic death after the
administration of capecitabine was described by Largillier
et al. in a breast cancer patient who displayed a deficient
phenotype and was demonstrated to be heterozygous for the
IVS14+1G>A polymorphism [46]. Many other polymor-
phisms have been reported as responsible of the severe
toxicity after 5-FU administration (Table 1). van Kuilenburg
et al. analyzed the DPD gene of 14 patients with a reduced
DPD activity and the analysis revealed the presence of
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mutations in 11 out of 14 patients and five patients showed
multiple mutations in the coding region of the DPD gene. In
four patients it was detected the missense mutation 85 T>C,
whereas the splice site mutation IVS14+1G>Awas detected
in six subjects. One patient was homozygous for the 2194G>
A mutation, whereas three patients were heterozygous for the
1627A>G mutation and two patients were homozygous for
the 496A>G and 2846A>T. The 2846A>T variant has also
been detected in a patient with a complete DPD deficiency
[47, 48]. Gross et al. analyzed four individuals with
symptoms of 5-FU-related toxicity and detected six sequence
variants in the DPD. Among them, 775A>G was found in a
breast cancer patient who had received CMF polychemo-
therapy and displayed severe toxicity. None of a control
cohort of 157 healthy individuals displayed this variant,
suggesting that the base pair change might be a deleterious
mutation and the novel mutation was present together with
the known 85 T>C. Another patient, treated with CMF due
to invasive breast carcinoma, carried four missense muta-
tions 85 T>C, 496A>G, 1601G>A, and 1627A>G. The
compound heterozygote genotype did not occur in any of the
157 control samples and had not been described previously.
The combination of 496A>G and 1601G>A was demon-
strated in a colon cancer patient showing unexpected toxicity
upon 5-FU administration. In the third patient, with invasive
breast carcinoma given 5-FU, epirubicin and cyclophospha-
mide, 85 T>C and the silent mutation 1896 T>C were found
in the coding area of DPD [41]. A meta-analysis of over 1200
patients suggested that more than 30% of patients treated with
5-FU experienced substantial drug-related toxicity [49].
However, genetic variants of DPD are not always associated
with severe 5-FU toxicity. Table 1 and 2 report some of the
more common SNPs identified in the DPD. While some
mutations are directly responsible for severe 5-FU side
effects, for example the IVS14+1G>A which is always
associated with high toxicity in cancer patients, others, like
the 1601G>A polymorphism, result in 5-FU related toxicity
only in combination with other genetic variants such as the
Polymorphism Localization Reference
61C>T, 62G>A, 74A>G exon 2 [47, 53]
187A>G exon 3 [55]
257C>T exon 4 [47]
601A>C exon 6 [47]
IVS6-29G>T splice site variant intron 6 [54]
703C>T exon 7 [59]
775A>G, 812delT exon 8 [41, 53]
1003G>T,1039-1042delTG, 1050G>A, 1108A>G exon 10 [47, 53, 55]
IVS10-15 T>C splice site variant intron 10 [21]
1156G>T exon 11 [53]
1358C>T exon 12 [22]
1590 T>C, 1679 T>G, 1714C>G exon13 [47, 53, 58]
1796 T>C, 1897delC exon 14 [23, 53]
2933A>G exon 23 [47]
Table 1 DPD polymorphisms
of unknown significance
Fig. 4 Schematic representation
of DPD gene structure and
polymorphisms
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496A>G [41]. Recent studies have also suggested that
epigenetic factors may influence DPD activity, such as an
aberrant methylation of the DPD promoter gene, which was
found to cause a partially DPD deficient phenotype [50–52].
Application of DPD screening in the clinical
setting: is it feasible?
While the uracil breath test and plasma uracil quantitation
to stratify patients for their risk of incurring in
fluoropyrimidine-induced toxicity are useful with some im-
portant limitations, the genomic approach appears to be
superior for indirect assessment of DPD. Although most of
the informations come from case reports or a few published
articles, the available clinical evidences obtained either
prospectively or retrospectively clearly identify IVS14+1G>
A as the most important mutation causing severe toxicity or
even death. Therefore, IVS14+1G>A testing should be
performed in patients before the first administration of
fluoropyrimidines or in those who suffered from severe
toxicities. The preliminary screening of other variants associ-
ated with less-severe adverse drug reactions before the
commencement of therapy is not justified. The following
approach may be suggested for patients never treated with
fluoropyrimidines or with fluoropyrimidine-induced toxicity
(Fig. 5). New patients are screened for the most important and
potentially lethal IVS14+1G>A mutation. If they are
negative, they may be treated with standard doses of the
drugs and then screened afterwards for other DPD variants if
they display toxicity after the first doses of treatment. If they
are heterozygous for IVS14+1G>A, the dose should be
reduced at least empirically or, preferably, after accurate
assessment of residual metabolic activity by DPD enzyme
activity of 5-FU-test dose (Fig. 5). If a patient treated with
fluoropyrimidines displays toxicity, he should be screened at
least for the variants listed in Table 1. If heterozygous for
IVS14+1G>A or hetero- or homozygous for other variants,
he should be treated by empirically reduced drug dose of after
phenotypic assessment (enzymatic DPD activity measure-
Fig. 5 Proposed algorithm for
screening DPD deficiency and
dose adjustment in patients
Table 2 DPD polymorphisms associated with toxicity by fluoropyr-
imidines
Polymorphism Localization Reference
85 T>C exon 2 [47]
464 T>A exon 5 [24]
496A>G exon 6 [21]
1109delTA exon 10 [21]
1601G>A, 1627A>G exon 13 [41, 57]
1896 T>C exon 14 [56]
IVS14+1G>A splice site variant intron 14 [56]
2194G>A exon 18 [47]
2846A>T exon 22 [21]
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ment or 5-FU pharmacokinetics). In all cases, patients
homozygous for IVS14+1G>A must not be treated with
fluoropyrimidines.
Conclusion and outlook
DPD deficiency plays an important role in the development
of fluoropyrimidine-associated severe toxicity. However, no
consensus exists on the clinical application of DPD
screening in the population of patients candidates to
fluoropyrimidine therapy. Herewith we propose the use of
a pharmacogenetic approach to identify patients at risk of
developing major toxicities and we present an algorithm
based on the preliminary screening of the most dangerous
polymorphism associated with severe toxicity and poten-
tially death by 5-FU and derivatives. The screening of
additional variants may be performed if toxicity occurs after
the administration of fluoropyrimidines to patients negative
for IVS14+1G>A.
Owing to the widespread use of these anticancer agents
in the treatment of patients and the availability of reliable
methods, the screening for the DPD variants should be
considered before the start of treatment to prevent the
occurrence of potentially lethal adverse reactions, particu-
larly in the adjuvant setting and in borderline patients. Due
to the multiple genetic variants of DPD gene, high-
throughput analysis platforms (i.e., SNP genotyping by
TaqMan, proteomic analysis) should be available in clinical
laboratories to make the access to DPD analysis easier for
the clinician with the goal of preventing toxic deaths
depending on inherited deficiency of DPD.
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